Resistance Mechanisms to Inhibitors of P53-MDM2 Interactions in Cancer Therapy: Can We Overcome Them?

Overview

Journal Cell Mol Biol Lett

Publisher Biomed Central

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2021 Dec 16

PMID 34911439

Citations 21

Authors

Lucia Haronikova

Ondrej Bonczek

Pavlina Zatloukalova

Filip Kokas-Zavadil

Martina Kucerikova

Philip J Coates

Robin Fahraeus

Borivoj Vojtesek

Affiliations

Soon will be listed here.

Abstract

Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the p53-binding domain of MDM2 and aim to disrupt the binding of MDM2 to p53. We describe the basic mechanism of action of these MDM2 inhibitors, such as nutlin-3a, summarise the determinants of sensitivity to MDM2 inhibition from p53-dependent and p53-independent points of view and discuss the problems with innate and acquired resistance to MDM2 inhibition. Despite progress in MDM2 inhibitor design and ongoing clinical trials, their broad use in cancer treatment is not fulfilling expectations in heterogenous human cancers. We assess the MDM2 inhibitor types in clinical trials and provide an overview of possible sources of resistance to MDM2 inhibition, underlining the need for patient stratification based on these aspects to gain better clinical responses, including the use of combination therapies for personalised medicine.

Citing Articles

TDP-43/ALKBH5-mediated mA modification of CDC25A mRNA promotes glioblastoma growth by facilitating G1/S cell cycle transition.

Zhang Y, Xie S, Li W, Gu J, Zhang X, Ni B MedComm (2020). 2025; 6(3):e70108.

PMID: 39974663 PMC: 11836349. DOI: 10.1002/mco2.70108.

Tumor hypoxia evidences the differential regulation of Mdm2-p53 axis by PTEN in tumor derived vs. normal endothelial cells.

Wilkus-Adamczyk K, Brodaczewska K, Kieda C Sci Rep. 2024; 14(1):31747.

PMID: 39738367 PMC: 11686244. DOI: 10.1038/s41598-024-82638-7.

Therapy-relevant amplification in cholangiocarcinomas in Caucasian patients.

Lyu S, Plum P, Fretter C, Simon A, Bedau T, Knipper K Ther Adv Med Oncol. 2024; 16:17588359241288123.

PMID: 39525665 PMC: 11550496. DOI: 10.1177/17588359241288123.

Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis.

Martinkova L, Zatloukalova P, Kucerikova M, Friedlova N, Tylichova Z, Zavadil-Kokas F Cell Mol Biol Lett. 2024; 29(1):117.

PMID: 39237877 PMC: 11378555. DOI: 10.1186/s11658-024-00637-y.

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition.

Pervushin N, Nilov D, Pushkarev S, Shipunova V, Badlaeva A, Yapryntseva M Apoptosis. 2024; 29(11-12):2197-2213.

PMID: 39222276 PMC: 11550243. DOI: 10.1007/s10495-024-02014-8.

References

Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A . Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 2000; 60(18):5278-83. View

Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J . p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene. 1999; 18(11):1921-34. DOI: 10.1038/sj.onc.1202528. View

Popowicz G, Czarna A, Holak T . Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle. 2008; 7(15):2441-3. DOI: 10.4161/cc.6365. View

Andreeff M, Kelly K, Yee K, Assouline S, Strair R, Popplewell L . Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2015; 22(4):868-76. PMC: 4809642. DOI: 10.1158/1078-0432.CCR-15-0481. View

Joseph T, Madhumalar A, Brown C, Lane D, Verma C . Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle. 2010; 9(6):1167-81. DOI: 10.4161/cc.9.6.11067. View

Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S . Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015; 58(16):6348-58. DOI: 10.1021/acs.jmedchem.5b00810. View

Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S . Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia. 2009; 23(11):2090-101. DOI: 10.1038/leu.2009.171. View

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros L . Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia. 2009; 23(4):784-90. DOI: 10.1038/leu.2008.348. View

10.

Valentine J, Kumar S, Moumen A . A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer. 2011; 11:79. PMC: 3050855. DOI: 10.1186/1471-2407-11-79. View

11.

Gessier F, Kallen J, Jacoby E, Chene P, Stachyra-Valat T, Ruetz S . Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode. Bioorg Med Chem Lett. 2015; 25(17):3621-5. DOI: 10.1016/j.bmcl.2015.06.058. View

12.

Seipel K, Marques M, Sidler C, Mueller B, Pabst T . The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. Cancers (Basel). 2018; 10(6). PMC: 6025168. DOI: 10.3390/cancers10060170. View

13.

Chang Y, Graves B, Guerlavais V, Tovar C, Packman K, To K . Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013; 110(36):E3445-54. PMC: 3767549. DOI: 10.1073/pnas.1303002110. View

14.

Guo G, Yu M, Xiao W, Celis E, Cui Y . Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Cancer Res. 2017; 77(9):2292-2305. PMC: 5465961. DOI: 10.1158/0008-5472.CAN-16-2832. View

15.

Riemenschneider M, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus J . Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 2000; 59(24):6091-6. View

16.

Yang P, Chen W, Li X, Eilers G, He Q, Liu L . Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Oncotarget. 2016; 7(22):32652-63. PMC: 5078041. DOI: 10.18632/oncotarget.8999. View

17.

Hou H, Sun D, Zhang X . The role of amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int. 2019; 19:216. PMC: 6704499. DOI: 10.1186/s12935-019-0937-4. View

18.

Supiot S, Hill R, Bristow R . Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther. 2008; 7(4):993-9. DOI: 10.1158/1535-7163.MCT-07-0442. View

19.

Medina-Medina I, Garcia-Beltran P, de la Mora-de la Mora I, Oria-Hernandez J, Millot G, Fahraeus R . Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions. Mol Cell Biol. 2016; 36(16):2195-205. PMC: 4968209. DOI: 10.1128/MCB.00113-16. View

20.

Vaseva A, Marchenko N, Moll U . The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle. 2009; 8(11):1711-9. PMC: 2823264. DOI: 10.4161/cc.8.11.8596. View